FLOWERFIELDS
Early-stage tumour markers based on the Flower proteins
| Coordinatore | UNIVERSITAET BERN
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | Switzerland [CH] |
| Totale costo | 154˙800 € |
| EC contributo | 138˙030 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2012-PoC |
| Funding Scheme | CSA-SA(POC) |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-02-01 - 2014-01-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITAET BERN
Organization address
address: Hochschulstrasse 4 contact info |
CH (BERN) | hostInstitution | 138˙030.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'It is unquestioned that early detection of cancer is a major factor contributing to therapy outcome. Unfortunately, only few tumour markers have been identified for early stage cancers to date, and the reliable detection of tumours before the manifestation of morphological changes still remains an unresolved problem in routine clinical diagnosis. A recent study came to the conclusion that shedding rates of currently available cancer biomarkers are a factor of 10-4 below the necessary sensitivity to reliably detect cancers during their first decade. In other studies, the reliability of currently existing biomarkers such as the PSA-marker for prostate cancer is questioned. The development of alternative early-stage tumour markers, in particular also for epithelial cancers, is therefore urgently necessary. FLOWERFIELDS is aimed to provide means and methods to detect such cancer cells before an aggressive tumour is formed. To that end, we plan to exploit the extracellular molecular code called “The Flower Code” (Fwe) that is expressed in very early stage cancer or precancerous cells. Fwe may be integrated into routine immuno- or PCR-assays for the detection of a variety of epithelial cancers. Applications may include early-stage diagnosis but also the evaluation of therapy outcome. The current project has two aims: (i) to develop improved ligands for ELISA diagnostic tests for Flower gene expression, (ii) to validate the concept clinically on human samples in both immuno- and PCR-based assays. The clinical validation of a biomarker candidate is a key success factor for being able to feed it into development stage of a commercial partner.'